NEUROCRINE BIOSCIENCES INC Restricted Cash and Cash Equivalents
NEUROCRINE BIOSCIENCES INC (NBIX) had Restricted Cash and Cash Equivalents of $8.00 million as of 2023-09-30, per its 10-Q filed 2023-10-31.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2023-10-31
- 2023-09-30: Restricted Cash and Cash Equivalents $8.00M.
- 2023-06-30: Restricted Cash and Cash Equivalents $168.20M.
- 2023-03-31: Restricted Cash and Cash Equivalents $111.60M.
- 2022-12-31: Restricted Cash and Cash Equivalents $270.70M.
| Period end | Restricted Cash and Cash Equivalents | Restricted Cash and Cash Equivalents as first filed |
|---|---|---|
| 2023-09-30 | $8.00M 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $168.20M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $111.60M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $270.70M 10-K · filed 2023-02-09 | |
| 2022-09-30 | $7.80M 10-Q · filed 2023-10-31 | $220.00M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $171.10M 10-Q · filed 2023-08-01 | |
| 2022-03-31 | $278.00M 10-Q · filed 2023-05-03 | |
| 2021-12-31 | $344.00M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $314.30M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | $371.20M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $355.80M 10-Q · filed 2022-05-04 | |
| 2020-12-31 | $190.30M 10-K · filed 2022-02-11 | |
| 2020-09-30 | $428.50M 10-Q · filed 2021-11-01 | |
| 2020-06-30 | $418.30M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $190.20M 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $115.50M 10-K · filed 2021-02-05 | $115.48M 10-K · filed 2020-02-07 |
| 2019-09-30 | $171.81M 10-Q · filed 2019-11-04 | |
| 2018-12-31 | $147.19M 10-K · filed 2020-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |